GRI Bio, Inc. (GRI)

GRI Bio, Inc.'s stock price experienced a substantial decline of 97.81% from January 10, 2025, to January 8, 2026. The company announced and closed an $8.0 million public offering in December 2025, following an earlier launch of a $6.7 million public offering, and expanded its at-the-market equity offering capacity in January 2026. The stock rose following the announcement of additional positive Phase 2a immune data for its IPF treatment, GRI-0621, on January 8, 2026, after announcing positive topline data from its Phase 2a study in IPF in December 2025. GRI Bio's price target was decreased by 77.56% in December 2025. The company regained compliance with Nasdaq's minimum bid price rule in March 2025. GRI Bio reported a net loss of $6.3 million for the nine months ended September 30, 2024, and confirmed its GRI-0621 Phase 2a IPF trial was on track for interim data in Q2 2025 and topline data in Q3 2025 in May 2025.

The provided information does not indicate any specific demand seasonality for GRI Bio, Inc.'s products or services. Demand for its products, once approved, would likely be driven by the prevalence and incidence of the conditions they treat, as well as the efficacy and safety profile of its treatments, rather than seasonal fluctuations.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for inflammatory, fibrotic, and autoimmune diseases by modulating Natural Killer T (NKT) cells. Its primary product candidates include GRI-0621, an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity in Phase 2a clinical development for idiopathic pulmonary fibrosis (IPF), and GRI-0803, a novel oral agonist of type 2 Natural Killer T (dNKT) cells in preclinical development for autoimmune disorders. The company also has a proprietary library of over 500 compounds.

GRI Bio, Inc. is headquartered in La Jolla, California, and primarily focuses its therapeutic development and commercialization efforts in the United States. The company has also expanded its clinical trial reach, having received authorization for a Phase 2a study in Australia and a Clinical Trial Application by the United Kingdom's Medicines and Healthcare products Regulatory Agency.

GRI Bio, Inc.'s brand reputation has been shaped by its clinical progress and financial activities. Positive developments include advancements in clinical trials, such as positive interim safety and biomarker results for GRI-0621 in its Phase 2a study for IPF in May 2025, and further positive topline data reported in December 2025, and additional positive immune data in January 2026. The company successfully closed public offerings in December 2025 and expanded its equity offering capacity in January 2026. Regaining compliance with Nasdaq's minimum bid price rule in March 2025 was also a positive signal.

The ownership structure of GRI Bio, Inc. includes institutional, insider, and retail investors. Major institutional shareholders include DRW Securities, LLC, Vanguard Group Inc, and BlackRock, Inc., holding approximately 3.08% to 4.47% of the company's stock. Joseph E. Payne is the largest individual shareholder, owning 26.35% of the company's shares, with other significant insider owners including Walter Marc Hertz (CEO) and Vipin Chaturvedi (CTO), with insiders collectively owning a substantial portion, ranging from 8.73% to 84.15% of the stock. Retail investors hold a significant portion of the stock, estimated at around 11.74% to 78.07%.